drugset / Trial / NCT06879691
A Trial of Nimotuzumab and Pinkiller Efficacy and Pain in Advanced Head and Neck Squamous Cell Carcinoma
Phase 4
Active not recruiting
171 enrolled
Biotech Pharmaceutical Co., Ltd.
Baotou Cancer Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate the impact of combining Nimotuzumab with analgesic agents on pain management outcomes, as well as the effectiveness and safety profile of this therapeutic combination in the comprehensive treatment of locally advanced head and neck squamous cell carcinoma.
Timeline
- Start
- 2021-05-15
- Primary completion
- 2025-04-14
- Completion
- 2025-04-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nimotuzumab | Monoclonal antibody | 200 mg | — |
| Background | Cisplatin | Other / unclassified | 30 mg/m2 | — |